[Advanced ovarian cancer: state of the art and future perspectives].

作者信息

Campisi C, Zappalà A, Terenzi S, Ravaioli M

机构信息

CNR-Istituto tecnologie biomediche, Roma.

出版信息

Tumori. 1998 May-Jun;84(3):A1-22.

PMID:9678630

Abstract

摘要

相似文献

[Advanced ovarian cancer: state of the art and future perspectives].

Tumori. 1998 May-Jun;84(3):A1-22.

DNA topoisomerases: from a laboratory curiosity to a subject in cancer chemotherapy.

NCI Monogr. 1987(4):3-6.

Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.

Int J Cancer. 1996 Aug 7;67(4):479-84. doi: 10.1002/(SICI)1097-0215(19960807)67:4<479::AID-IJC3>3.0.CO;2-P.

Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.

Cancer Res. 1994 Feb 1;54(3):749-55.

P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.

Cancer Res. 1991 Nov 1;51(21):5915-20.

DNA topoisomerases--new twists to tumour therapy.

Lancet. 1988 Mar 5;1(8584):512-3.

Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.

Clin Cancer Res. 2005 Aug 15;11(16):5912-9. doi: 10.1158/1078-0432.CCR-04-1240.

New options for the treatment of advanced ovarian cancer.

Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-2-S5-11.

Symposium: downstream from topoisomerase-DNA lesions: life-or-death consequences for the cell.

Cell Biochem Biophys. 2000;33(2):171-3. doi: 10.1385/CBB:33:2:171.

Recurrent ovarian cancer.

Clin Adv Hematol Oncol. 2005 Sep;3(9):723-36.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验